France· FR:68120522
ROMVIMZA 30 mg, gélule
A vimseltinib product containing vimseltinib dihydraté, registered in France by DECIPHERA PHARMACEUTICALS (NETHERLANDS) (PAYS-BAS). The same ATC class is registered in 10 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Vimseltinib is registered in 10 of 19 countries.
Countries holding a registration under ATC L01EX29 (vimseltinib), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 7 of them publish a price we can compare per daily dose
Vimseltinib · ATC L01EX29
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Spainprice
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- VIMSELTINIB DIHYDRATÉ
- Manufacturer
- DECIPHERA PHARMACEUTICALS (NETHERLANDS) (PAYS-BAS)
- Country
- France (FR)
- ATC code
- L01EX29
- ATC class
- Vimseltinib
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip133400930327012plaquette(s) thermoformée(s) OPA : polyamide orienté aluminium PVC avec fermeture de sécurité enfant de 8 gélule(s)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Vimseltinib in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesROMVIMZADeciphera Pharmaceuticals, LLC
- CzechiaROMVIMZADeciphera Pharmaceuticals (Netherlands) B.V., Amsterdam
- SpainROMVIMZA 30 MG CAPSULAS DURASDeciphera Pharmaceuticals (Netherlands) B.V.
- FinlandROMVIMZADeciphera Pharmaceuticals (Netherlands) B.V.
- IrelandROMVIMZA 30 mg hard capsulesDeciphera Pharmaceuticals (Netherlands) B.V.
- BelgiumRomvimza 30 mgDeciphera Pharmaceuticals (Netherlands)
- NetherlandsROMVIMZA 30 mg harde capsulesDeciphera Pharmaceuticals (Netherlands) B.V.
- PolandRomvimzaDeciphera Pharmaceuticals (Netherlands) B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Romvimza
- Liechtenstein · Romvimza
- Norway · Romvimza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/24a5ec30-65d7-4c09-b2b8-4c49f57f5a15 GET /v1/drugs/24a5ec30-65d7-4c09-b2b8-4c49f57f5a15?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68120522",
"date_amm": "2025-09-17",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/25/1968",
"substance": "VIMSELTINIB DIHYDRATÉ",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about vimseltinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.